Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity.

Zhang L, Liu W, Szumlinski KK, Lew J.

Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20041-6. doi: 10.1073/pnas.1212914109. Epub 2012 Nov 14.

2.

A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.

Zheng YL, Amin ND, Hu YF, Rudrabhatla P, Shukla V, Kanungo J, Kesavapany S, Grant P, Albers W, Pant HC.

J Biol Chem. 2010 Oct 29;285(44):34202-12. doi: 10.1074/jbc.M110.134643. Epub 2010 Aug 18.

3.

The protective effects of tanshinone IIA on neurotoxicity induced by β-amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons.

Shi LL, Yang WN, Chen XL, Zhang JS, Yang PB, Hu XD, Han H, Qian YH, Liu Y.

Neurochem Int. 2012 Jul;61(2):227-35. doi: 10.1016/j.neuint.2012.04.019. Epub 2012 Apr 25.

PMID:
22561406
4.

The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.

Hisanaga S, Saito T.

Neurosignals. 2003 Sep-Oct;12(4-5):221-9. Review.

PMID:
14673209
5.

Overexpression of p35 in Min6 pancreatic beta cells induces a stressed neuron-like apoptosis.

Zheng YL, Hu YF, Zhang A, Wang W, Li B, Amin N, Grant P, Pant HC.

J Neurol Sci. 2010 Dec 15;299(1-2):101-7. doi: 10.1016/j.jns.2010.08.067.

PMID:
20926102
6.

Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.

Kesavapany S, Zheng YL, Amin N, Pant HC.

Biotechnol J. 2007 Aug;2(8):978-87. Review.

PMID:
17526058
7.

Neurotoxicity induces cleavage of p35 to p25 by calpain.

Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH.

Nature. 2000 May 18;405(6784):360-4.

PMID:
10830966
8.

Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylation.

Kamei H, Saito T, Ozawa M, Fujita Y, Asada A, Bibb JA, Saido TC, Sorimachi H, Hisanaga S.

J Biol Chem. 2007 Jan 19;282(3):1687-94. Epub 2006 Nov 22.

9.

Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation.

Corbel C, Zhang B, Le Parc A, Baratte B, Colas P, Couturier C, Kosik KS, Landrieu I, Le Tilly V, Bach S.

Chem Biol. 2015 Apr 23;22(4):472-82. doi: 10.1016/j.chembiol.2015.03.009. Epub 2015 Apr 9.

10.

No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro.

Peterson DW, Ando DM, Taketa DA, Zhou H, Dahlquist FW, Lew J.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2884-9. doi: 10.1073/pnas.0912718107. Epub 2010 Feb 1.

11.

Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.

Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH.

Nature. 1999 Dec 9;402(6762):615-22.

PMID:
10604467
12.

Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation.

Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttilä T.

Biochem Biophys Res Commun. 2002 Nov 15;298(5):693-8.

PMID:
12419309
13.

Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease.

Alvira D, Tajes M, Verdaguer E, Acuña-Castroviejo D, Folch J, Camins A, Pallas M.

J Pineal Res. 2006 Apr;40(3):251-8.

PMID:
16499562
14.

The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.

Amin ND, Zheng Y, Bk B, Shukla V, Skuntz S, Grant P, Steiner J, Bhaskar M, Pant HC.

Mol Biol Cell. 2016 Nov 1;27(21):3221-3232. Epub 2016 Sep 14.

15.

Phosphorylation of cyclin-dependent kinase 5 (Cdk5) at Tyr-15 is inhibited by Cdk5 activators and does not contribute to the activation of Cdk5.

Kobayashi H, Saito T, Sato K, Furusawa K, Hosokawa T, Tsutsumi K, Asada A, Kamada S, Ohshima T, Hisanaga S.

J Biol Chem. 2014 Jul 11;289(28):19627-36. doi: 10.1074/jbc.M113.501148. Epub 2014 May 28.

16.

Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene.

Patzke H, Maddineni U, Ayala R, Morabito M, Volker J, Dikkes P, Ahlijanian MK, Tsai LH.

J Neurosci. 2003 Apr 1;23(7):2769-78.

17.
18.

Targeting p35/Cdk5 signalling via CIP-peptide promotes angiogenesis in hypoxia.

Bosutti A, Qi J, Pennucci R, Bolton D, Matou S, Ali K, Tsai LH, Krupinski J, Petcu EB, Montaner J, Al Baradie R, Caccuri F, Caruso A, Alessandri G, Kumar S, Rodriguez C, Martinez-Gonzalez J, Slevin M.

PLoS One. 2013 Sep 30;8(9):e75538. doi: 10.1371/journal.pone.0075538. eCollection 2013 Sep 30.

19.

Deregulation of cdk5 in Hippocampal sclerosis.

Sen A, Thom M, Martinian L, Jacobs T, Nikolic M, Sisodiya SM.

J Neuropathol Exp Neurol. 2006 Jan;65(1):55-66.

PMID:
16410749
20.

Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.

Li G, Faibushevich A, Turunen BJ, Yoon SO, Georg G, Michaelis ML, Dobrowsky RT.

J Neurochem. 2003 Jan;84(2):347-62.

Supplemental Content

Support Center